Consensus Ionis Pharmaceuticals, Inc.

Stocks

IONS

US4622221004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 22:33:26 06/11/2026 +04			5-day change	1st Jan Change
39.88 ^USD	+2.80%		-9.58%	-50.26%

11-02	Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target	RE
10-22	Wall Street, Please Make Up Your Mind on AI

Evolution of the Average Target: Ionis Pharmaceuticals, Inc.

Evolution of the Target Price: Ionis Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Ionis Pharmaceuticals, Inc.

375638633c433a11e7ce.k0l2Qb2_lzIIPcd0pn1xerB5O7iw72sTwvPFk6xiyEk._gg1MNHm5wE7f55MyCkZHdk6TvHVoBhF74GcoOY4mQTFLS8LyY7EdT1k_w~0988e102bcbe926ce29c5d98f1c62359

Analysts' recommendations: Ionis Pharmaceuticals, Inc.

10-22	BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform	MT
10-22	Analyst recommendations: Block, Halliburton, Qiagen, Tesla, CoreWeave…
10-15	Ionis Pharmaceuticals Shares Rise After UBS Upgrade	MT
10-15	UBS Upgrades Ionis Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $88 From $46	MT
09-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $91 From $93	MT
09-03	Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial	RE
07-13	RBC Cuts Price Target on Ionis Pharmaceuticals to $85 From $100, Keeps Outperform Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	Analyst recommendations: Cubesmart, Fox Corporation, AMD, Crowdstrike, Micron…
07-09	Needham Adjusts Ionis Pharmaceuticals Price Target to $86 From $105, Maintains Buy Rating	MT
07-09	TD Cowen Adjusts Ionis Pharmaceuticals Price Target to $94 From $108, Maintains Buy Rating	MT
07-09	WINNERS & LOSERS: Astra down on failed test; Computacenter ups outlook	AN
04-30	Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating	MT
04-30	RBC Lifts Price Target on Ionis Pharmaceuticals to $100 From $95, Keeps Outperform Rating	MT
04-21	Canaccord Genuity Initiates Coverage on Ionis Pharmaceuticals With Buy Rating, $110 Price Target	MT
04-21	Analyst recommendations: Colgate-Palmolive, Intel, Netflix, Spotify, Dell…
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	BofA Adjusts Price Target on Ionis Pharmaceuticals to $111 From $100, Maintains Buy Rating	MT
12-17	RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
30/10/25	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
28/10/25	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
16/10/25	Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
08/10/25	Ionis Pharmaceuticals Shares Rise After JPMorgan Upgrade	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IONIS PHARMACEUTICALS, INC.					+116.83%
	WUXI APPTEC CO., LTD.					+31%
	ARGENX SE					+22.4%
	LONZA GROUP AG					+4.89%
	IQVIA HOLDINGS INC.					+17.75%
	BEONE MEDICINES AG					+12.99%
	REVOLUTION MEDICINES, INC.					+45.7%
	CELLTRION, INC.					+27.37%
	GENMAB A/S					+10.13%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.84%
	Average					+31.29%
	Weighted average by Cap.					+23.09%